Holen Sie sich die Stockscreener-App
3.19
5.63%
0.17
Handel nachbörslich:
3.20
0.01
+0.31%
Mannkind Corp Aktie (MNKD) Neueste Nachrichten
MannKind to Participate in the Chardan Healthcare Conference - GlobeNewswire Inc.
A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein. - Stock Titan
New data supports Furoscix ReadyFlow autoinject... - Pluang
MannKind Presents New Data Showing Furoscix ReadyFlow Delivers IV-Equivalent Diuresis Across Injection Sites at HFSA 2026 - Quiver Quantitative
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) - GlobeNewswire Inc.
MNKD Maintains Buy Rating -- Price Target Lowered to $5.00 by Truist Securities - GuruFocus
MannKind stock weighs 43 percent revenue growth against losses - AD HOC NEWS
Delaware Court Ruling Boosts MannKind (MNKD) Outlook Amid Liquid - GuruFocus
MNKD Stock Draws Trader Focus On Rose Pharma GLP-1 Deal - StocksToTrade
MNKD Stock In Focus After Rose Pharma GLP-1 Licensing Deal - timothysykes.com
MNKD Stock In Focus After Rose Pharma GLP-1 Licensing Deal - timothysykes.com
Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com South Africa
Director Steven Binder Sells 39,051 Shares of MannKind Corp (MNK - GuruFocus
Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com Nigeria
Form 4 MannKind Corp For: 28 September By Investing.com - Investing.com Nigeria
Steven Binder sells $128,477 of MannKind (MNKD) stock - Investing.com
Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com Canada
Form 144 MannKind Corporation For: 25 September - Investing.com India
Form 144 MannKind Corporation For: 25 September By Investing.com - Investing.com Canada
Shares valued at $128,478 are proposed for sale by MannKind (MNKD) director Steven Binder. - Stock Titan
Danbury Company Reports Positive Results In Lung Disease Drug Trial - Patch
MannKind Corporation (MNKD) Options ChainYahoo Finance - Yahoo! Finance Canada
MannKind Corporation (MNKD) Stock Analysis: Exploring a 127.68% Potential Upside in the Biotech Space - DirectorsTalk Interviews
MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost - Stocktwits
Mannkind Stock Price Forecast. Should You Buy MNKD? - StockInvest.us
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum - TradingView
MannKind (MNKD) Bets On Inhaled Weight Loss Amid Widening Losses - Yahoo Finance
Cantor Fitzgerald reiterates Overweight on MannKind stock at $8 By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight rating on MannKind stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight on MannKind stock at $8 By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Overweight rating on MannKind stock By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Overweight on MannKind stock at $8 By Investing.com - Investing.com India
Cantor Fitzgerald reiterates Overweight rating on MannKind stock - investing.com
MNKD Reiterates by Cantor Fitzgerald -- Price Target Maintained at $6.50 - GuruFocus
MannKind (NASDAQ: MNKD) director lines up more stock sales under trading plan - stocktitan.net
CT drugmaker partners on development of inhaled weight-loss treatment - Hartford Business Journal
MannKind inks obesity deal with Rose Pharma - thepharmaletter.com
Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule - Benzinga
MannKind signs global GLP-1 inhalation collaboration deal - grafa.com
MannKind Expands Into Weight Loss With Rose Pharma Deal – Here’s What Investors Are Watching - Yahoo Finance
MNKD Looks 44.2% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
MNKD Looks 44.2% Undervalued on GF Value™ Amid Speculative Growt - GuruFocus
MannKind partners with Rose Pharma on inhaled GLP-1 therapy By Investing.com - Investing.com India
MannKind partners with Rose Pharma on inhaled GLP-1 therapy - investing.com
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management - The Manila Times
MannKind and Rose Pharma Enter Worldwide Collaboration to Develop Inhaled ROSE-010 Technosphere for Weight Management - Quiver Quantitative
MannKind and Rose Pharma Inc Enter Licensing and - GlobeNewswire
MannKind and Rose Pharma Inc Enter Licensing and - GlobeNewswire
A rapid-acting, short-duration inhaled treatment is being developed for weight management - stocktitan.net
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management - Yahoo Finance
7.94%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):